摘要
Objective:To explore the proportion and clinical predictive value of serum regulatory T cells (CD4+CD25+Treg cell) in the treatment process of chronic hepatitis C (CHC) by the interferon. Methods:A total of 94 patients with CHC who were admitted in our hospital for the treatment of peglyated interferon-α and ribavirin were included in the study and were divided into low, moderate, and high loading capacity groups according to HCV-RNA content before treatment. The correlation of different loading capacity with the clinical materials was analyzed. HCV-RNA and the proportion of peripheral blood CD4+CD25+Treg cells after treatment in patients with different response were detected and compared.Results: The comparison of the proportion of peripheral blood CD4+CD25+Treg cells and HCV-RNA among the three groups was statistically significant (P<0.05), and both of them were positively correlated (r=0.845, P=0.001). Among 94 patients, 90 patients had completed 48-week treatment, among which 55 had continuous response, 25 had partial response, and 10 had no response. The proportion of CD4+CD25+Treg cells in the continuous response group and partial response group was significantly reduced when compared with before treatment (P<0.05), while that in the no response group was significantly elevated when compared with before treatment (P<0.05). The comparison of the proportion of CD4+CD25+Treg cells 24 and 48 weeks after treatment among the three groups was statistically significant (P<0.05). CD3+, CD4+, CD8+, and CD4+/CD8+ after treatment in the continuous response and partial response groups were significantly elevated when compared with before treatment (P<0.05). The comparison of CD3+, CD4+, CD8+, and CD4+/CD8+ among the three groups was statistically significant (P<0.05). Conclusions:Interferon in the treatment of CHC can reduce HCV-RNA loading capacity and the proportion of CD4+CD25+Treg cells. HCV-RNA loading capacity in patients with CHC has no correlation with the gender and age, but is positively correlated with the proportion of peripheral blood CD4+CD25+Treg cells. The change of CD4+CD25+Treg cell level can provide a new thought to predict the efficacy in CHC patients.
